200 related articles for article (PubMed ID: 12682274)
1. Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates.
Hou Y; Gu XX
J Immunol; 2003 Apr; 170(8):4373-9. PubMed ID: 12682274
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx.
Hirano T; Hou Y; Jiao X; Gu XX
FEMS Immunol Med Microbiol; 2003 Jan; 35(1):1-10. PubMed ID: 12589951
[TBL] [Abstract][Full Text] [Related]
3. Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model.
Sun J; Chen J; Cheng Z; Robbins JB; Battey JF; Gu XX
Vaccine; 2000 Jan; 18(13):1264-72. PubMed ID: 10649628
[TBL] [Abstract][Full Text] [Related]
4. Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against Moraxella catarrhalis and nontypeable Haemophilus influenzae.
Singh S; Wilson JC; Cripps AW; Massa H; Ozberk V; Grice ID; Peak IR
Vaccine; 2020 Jan; 38(2):309-317. PubMed ID: 31668366
[TBL] [Abstract][Full Text] [Related]
5. Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.
Wu TH; Gu XX
Infect Immun; 1999 Oct; 67(10):5508-13. PubMed ID: 10496940
[TBL] [Abstract][Full Text] [Related]
6. Identification of common lipooligosaccharide types in isolates from patients with otitis media by monoclonal antibodies against nontypeable Haemophilus influenzae 9274.
Ueyama T; Gu XX; Tsai CM; Karpas AB; Lim DJ
Clin Diagn Lab Immunol; 1999 Jan; 6(1):96-100. PubMed ID: 9874671
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring bactericidal antibodies specific for Haemophilus influenzae lipooligosaccharide are present in healthy adult individuals.
Choi J; Nix EB; Gaultier GN; Cox AD; McCready W; Ulanova M
Vaccine; 2015 Apr; 33(16):1941-7. PubMed ID: 25738817
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.
Gu XX; Tsai CM; Ueyama T; Barenkamp SJ; Robbins JB; Lim DJ
Infect Immun; 1996 Oct; 64(10):4047-53. PubMed ID: 8926067
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae.
Gu XX; Rudy SF; Chu C; McCullagh L; Kim HN; Chen J; Li J; Robbins JB; Van Waes C; Battey JF
Vaccine; 2003 May; 21(17-18):2107-14. PubMed ID: 12706701
[TBL] [Abstract][Full Text] [Related]
10. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
[TBL] [Abstract][Full Text] [Related]
11. Investigation of non-typeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines.
Wu T; Chen J; Murphy TF; Green BA; Gu XX
Vaccine; 2005 Oct; 23(44):5177-85. PubMed ID: 16039021
[TBL] [Abstract][Full Text] [Related]
12. Protection against nontypeable Haemophilus influenzae challenges by mucosal vaccination with a detoxified lipooligosaccharide conjugate in two chinchilla models.
Hong W; Peng D; Rivera M; Gu XX
Microbes Infect; 2010 Jan; 12(1):11-8. PubMed ID: 19782149
[TBL] [Abstract][Full Text] [Related]
13. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas.
Gu XX; Sun J; Jin S; Barenkamp SJ; Lim DJ; Robbins JB; Battey J
Infect Immun; 1997 Nov; 65(11):4488-93. PubMed ID: 9353024
[TBL] [Abstract][Full Text] [Related]
14. Modified lipooligosaccharide structure protects nontypeable Haemophilus influenzae from IgM-mediated complement killing in experimental otitis media.
Langereis JD; Stol K; Schweda EK; Twelkmeyer B; Bootsma HJ; de Vries SP; Burghout P; Diavatopoulos DA; Hermans PW
mBio; 2012; 3(4):e00079-12. PubMed ID: 22761391
[TBL] [Abstract][Full Text] [Related]
15. Antisera Against Certain Conserved Surface-Exposed Peptides of Nontypeable Haemophilus influenzae Are Protective.
Whitby PW; Seale TW; Morton DJ; Stull TL
PLoS One; 2015; 10(9):e0136867. PubMed ID: 26390432
[TBL] [Abstract][Full Text] [Related]
16. Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity.
McMahon M; Murphy TF; Kyd J; Thanavala Y
Vaccine; 2005 May; 23(27):3590-6. PubMed ID: 15855018
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media.
Winter LE; Barenkamp SJ
Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28768669
[TBL] [Abstract][Full Text] [Related]
18. Passive transfer of antiserum specific for immunogens derived from a nontypeable Haemophilus influenzae adhesin and lipoprotein D prevents otitis media after heterologous challenge.
Kennedy BJ; Novotny LA; Jurcisek JA; Lobet Y; Bakaletz LO
Infect Immun; 2000 May; 68(5):2756-65. PubMed ID: 10768970
[TBL] [Abstract][Full Text] [Related]
19. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model.
Kyd JM; Dunkley ML; Cripps AW
Infect Immun; 1995 Aug; 63(8):2931-40. PubMed ID: 7622215
[TBL] [Abstract][Full Text] [Related]
20. A bacterial vaccine polypeptide protective against nontypable Haemophilus influenzae.
Whitby PW; Morton DJ; Mussa HJ; Mirea L; Stull TL
Vaccine; 2020 Mar; 38(14):2960-2970. PubMed ID: 32111525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
